Analyst Price Targets — QTTB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 1:37 pm | Derek Archila | Wells Fargo | $66.00 | $20.29 | TheFly | Q32 Bio upgraded to Overweight at Wells Fargo after alopecia areata study data |
| July 13, 2026 1:32 pm | — | Oppenheimer | $40.00 | $20.72 | StreetInsider | Q32 Bio Inc. (QTTB) PT Raised to $40 at OppenheimerMember Login |
| May 22, 2026 8:33 am | Joseph Catanzaro | Mizuho Securities | $14.00 | $5.50 | TheFly | Q32 Bio initiated with an Outperform at Mizuho |
| March 10, 2026 4:20 pm | Joseph Pantginis | H.C. Wainwright | $13.00 | $5.99 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key clinical data" |
| December 5, 2024 9:10 pm | Etzer Darout | BMO Capital | $64.00 | $23.69 | StreetInsider | BMO Capital Starts Q32 Bio Inc. (QTTB) at Outperform |
| October 16, 2024 6:22 am | Jay Olson | Oppenheimer | $80.00 | $48.47 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB) |
| September 11, 2024 5:27 am | Derek Archila | Wells Fargo | $95.00 | $50.61 | StreetInsider | Wells Fargo Starts Q32 Bio Inc. (QTTB) at Overweight |
| May 21, 2024 6:22 am | Thomas Smith | Leerink Partners | $54.00 | $30.20 | TheFly | Q32 Bio initiated with an Outperform at Leerink |
| April 10, 2024 4:02 pm | Jay Olson | Oppenheimer | $50.00 | $21.48 | StreetInsider | Oppenheimer Starts Q32 Bio Inc. (QTTB) at Outperform |
| April 2, 2024 5:02 am | Christopher Raymond | Raymond James | $45.00 | $18.00 | TheFly | Q32 Bio initiated with an Overweight at Piper Sandler |
Latest News for QTTB
Q32 Bio's Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients. Bempikibart also seems to be relatively safe, and its treatment benefits appear to last well after finishing treatment. These factors could help differentiate Bempikibart from other continuously dosed JAK inhibitors.
The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to…
The biotech is advancing a potential treatment for a common autoimmune disease.
Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction and up to 40% of severe AA patients reaching SALT 20. Bempikibart's improved safety, durable efficacy, and maintenance dosing potential position it as a first-line alternative to JAK inhibitors.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTTB.
U.S. House Trading
No House trades found for QTTB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.